Vir Biotechnology Seeks to Raise $200 Million in Public Offering In the competitive landscape of biopharmaceutical innovation, where securing capital is crucial for advancing groundbreaking treatments, Vir Biotechnology, Inc. stands out. The company, focused on harnessing the immune system to…
Positive Opinion Paves Way for Phase III Trial of Acetylleucine in Rare Neurological Conditions Why are rare neurological disorders often overlooked in drug development? IntraBio Inc., an Austin, Texas-based global biopharmaceutical company, is addressing this gap by advancing a potential treatment…
Biotech Firm to Present at Psychedelic Therapeutics Conference in New Orleans Why are current treatments for neurodegenerative diseases often limited to symptom management? Five Discovery, a biotechnology company, is addressing this gap by developing small-molecule therapeutics to repair dysfunctional brain…
Global Healthcare Leader Organon Licenses Sebela Pharmaceuticals’ MIUDELLA for Diverse Reproductive Health Needs Why is the landscape of women’s reproductive health evolving so rapidly? Organon a global healthcare company with a mission to deliver impactful medicines and solutions for a…
Biotech Pioneer SylamoreBio Collaborates with Daiichi Sankyo to Tackle CNS Delivery Challenges How can biotech companies overcome the formidable barriers to delivering therapies to the central nervous system (CNS)? SylamoreBio, a biotechnology company dedicated to advanced therapeutic delivery, is addressing…
BXLS and Johnson & Johnson Collaborate to Fund Bleximenib Clinical Trials for AML Why is the development of new treatments for acute myeloid leukemia (AML) so critical? Despite being the most common acute leukemia in adults, AML remains an extremely…
Positive Top-Line Results for Reblozyl in Alpha-Thalassemia Study Is the treatment landscape for alpha-thalassemia about to change? Bristol Myers Squibb has announced positive top-line results from an ongoing, ex-US, Phase 2 registrational study evaluating Reblozyl® (luspatercept-aamt) versus placebo for anemia…
Merck Evolves Structure to Enhance Commercial Execution and Portfolio Growth In an industry where the pace of innovation and market dynamics are constantly evolving, how can pharmaceutical companies ensure they stay ahead? Merck known as MSD outside of the United…
Dr. Reddy’s Announces USFDA Acceptance to Review Its Biologics License Application (BLA) for Proposed Interchangeable Biosimilar, Abatacept Dr. Reddy’s Laboratories Ltd. along with its subsidiaries together referred to as “Dr. Reddy’s”), today announced that the US Food and Drug Administration…
Seaport Therapeutics Presents New Meta-Analysis Examining the Impact of Clinical Trial Design Factors on Placebo Response in Generalized Anxiety Disorder Trials Seaport Therapeutics a clinical-stage therapeutics company advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the…
FDA Accepts New Drug Application for Genentech’s Giredestrant in ESR1-Mutated, ER-Positive Advanced Breast Cancer Genentech, a member of the Roche Group announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s New Drug Application for giredestrant,…
YolTech Therapeutics Announces Positive Interim Data on YOLT-202 for the Treatment of Alpha-1 Antitrypsin Deficiency YolTech Therapeutics, a late clinical-stage biotechnology company developing in vivo gene editing therapies, today announced positive interim data from an investigator-initiated trial (IIT) of YOLT-202,…